Literature DB >> 8818662

Cohabiting t(12;22) and inv(3) primary rearrangements in an acute myelomonocytic leukemia (FAB M4) cell line.

R A MacLeod1, Z B Hu, M Kaufmann, H G Drexler.   

Abstract

We describe the cytogenetic characterization of MUTZ-3, the first continuous cell line to be established from acute myelomonocytic leukemia (FAB M4) cells, exhibiting recurrent chromosomal rearrangements associated with this disease category. MUTZ-3 was established from peripheral blood taken at presentation from a 29-year-old male patient and carries the t(12;22)(p13.2;q11.2) associated with acute myelomonocytic leukemia (AMMoL), the inv(3)(q21.2q26.3) associated with multilineage acute myeloid leukemias (AML), and the inv(7)(p 14q35) associated with ataxia telangiectasia (A-T). There was no evidence that the patient was an A-T heterozygote. The breakpoint on chromosome 22 mapped between 5' BCR and D22S39, consistent with the G-banding assignment. Both inversions were translocation-associated and may be further examples of an association previously described in AML FAB M4eo with inv(16). We suggest that the combination of inv(3)/t(3;3) with t(12;22) may represent a new, nonrandom association in AML.

Entities:  

Mesh:

Year:  1996        PMID: 8818662     DOI: 10.1002/(SICI)1098-2264(199606)16:2<144::AID-GCC9>3.0.CO;2-#

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  2 in total

1.  A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report.

Authors:  Suning Chen; Stefan Nagel; Bjoern Schneider; Haiping Dai; Robert Geffers; Maren Kaufmann; Corinna Meyer; Claudia Pommerenke; Kenneth S Thress; Jiao Li; Hilmar Quentmeier; Hans G Drexler; Roderick A F MacLeod
Journal:  Cell Oncol (Dordr)       Date:  2017-11-08       Impact factor: 6.730

2.  NKL Homeobox Gene VENTX Is Part of a Regulatory Network in Human Conventional Dendritic Cells.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Hans G Drexler
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.